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Twenty.six adult patients with preformed IgG donor 
lymphocytotoxic antibodies received primary liver 
allografts under FK 508 immunosuppression. The 
effect of the crossmatch·positive state on early graft 
function and on the immunopathological and histo-
pathological findings was compared with that of 52 
crollSlDatch-negative control recipients. The presensi· 
tized (Cl"088Dlatch-positive) patients had prolongation 
of early graft dysfunction., underwent more clinically 
indicated biopsies and had a higher incidence of 
cellular rejection, both overall (p < 0.05) and within 10 
days of transplantation (p < 0.01). They also had a 
higher incidence of graft failure in the first 180 days 
(p < 0.01). Hyperacute rejection with necrotizing or 
neutrophilic arteritis was not seen in the crossmatch-
positive grafts. However, histological findings asso-
ciated with presensitization included platelet margin-
ation in central veins and sinusoids in biopsy spec-
imens 60 to 90 min after graft revascularization. Later 
biopsy specimens had neutrophilic portal venulitis 
followed by cholangiolar proliferation, acute cholan-
giolitis and centrilobular hepatocyte swelling that 
mimicked preservation injury, endothelial activation 
of arteries with medial changes and relapsing episodes 
of acute cellular rejection. These clinicopathological 
observations suggest that lymphocytotoxic antibodies 
can have a deleterious effect on liver allograft function 
and survival, even if they do not precipitate immediate 
or hyperacute rejection. (IIEPATOLOGY 1992;18:671-
681.) 
Although the liver is known to be more resistant than 
other solid organs to injury from preformed graft 
antibodies in the recipient (1-3), this privileged state is 
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not absolute (4,5). Identification of the consequences of 
humoral antibody states on the liver has been hampered 
by the lack of distinctive pathological findings in many 
cases in which humoral rejection was suspected but was 
not proved. Consequently, in this study of liver recip-
ients with preformed donor lymphocytotoxic antibodies, 
we have attempted to determine whether a unique, 
pathologically identifiable fonn of graft injury could be 
recognized and whether pathophysiological mechanisms 
of liver allograft injury could be deduced. A similar study 
on the pathological nature of ABO-mismatched livers in 
which the graft antibodies were isoagglutinins was 
published recently (6). 
MATERIALS AND METHODS 
Patient Selection. During the l1-mo period between 
November 31,1989, and September 9,1990,243 adult patients 
( > 16 yr) were given primary liver allografts under FK 506 and 
low-dose steroid therapy. The sera of26 (11 %) contained donor 
lymphocytotoxic antibodies. The crossmatch-negative control 
patients (n = 52) were those treated just before and after the 
crossmatch-positive cases. Most of these same cases were part 
of a recent clinical report (5). There were no statistically 
significant differences between the two cohorts with respect to 
age, United Network of Organ Sharing urgency of need status, 
original disease, donor demographic data or cold ischemic time 
(Table 1). More women had positive crossmatches (Table 1). 
The donor and recipient patients had the same ABO blood type 
in all cases. 
Cro .. motch Test. Recipient sera were obtained immediately 
before liver transplantation and tested for cytotoxic antibody 
activity against T lymphocytes isolated from donor lymph 
nodes at room temperature (370 C), followed by a 60 min 
incubation period with rabbit complement. Target cell lysis 
was determined by trypan blue exclusion. The crossmatch test 
was interpreted as positive when more than 50% of donor 
lymphocytes were killed. If the screening test was positive, the 
recipient serum was pretreated with dithiothreitol (DIT) for 
30 min to inactivate the IgM antibodies, which have been 
shown to be less deleterious in kidney transplantation (7). The 
26 cross match-positive results were after DTT treatment. 
Clinical Follow-up, ImmuJUMuppreuive Rl!gimen and Sta-
mticalAnalyag. Clinical follow-up was to April 1, 1991 (Table 
2), allowing potential follow-ups of 203 to 493 days for the 
671 
f 
i ,. 
I 
~ 
. 
l 
.., 
>'i 
... 
672 DEMETRIS ET AL. HEpATOLOGY 
TABLE 1. Clinical data of croll8llUltch'positive patients and controlll 
Characterietica Croumatch-Pollitive Control 
No. of patients 26 52 
Age (yr)Q (range) 51.4 :!: 9.4 (29-65) 45.7 :!: 14.0 (17-66) 
Sex (M!F) 11115 29/23 
United Network of Organ Sharing class" 3.7 :!: 0.5 3.6 :!: 0.7 
Blood type (A : B : AB : 0) 10 : 1:3:12 20 :6: 1: 25 
Cold ischemic time (min)Q (range) 927 :!: 278 (450-1631) 838 :!: 280 (265-1643) 
Original disease 
CAHlcirrhosis 8 14 
Alcoholism 5 13 
PBC 4 4 
PSC 3 3 
Biliary cirrhosis 0 6 
AHN 0 2 
Neoplasia 3 2 
Others 3 8 
PSC = primary sclerosing cholangitis; AHN = acute hepatic necrosis; OLT = orthotopic liver transplantation. 
QExpressed as mean :!: S.D. 
TABLE 2. Clinicopathological summary of crolllllllatch·positive primary liver allograft recipients 
Graft Patient 
Donor crr 
Cue OLTno. Ale (yr) S_ UNOS ABO (apJIeKIABOl (hrlmin) staiu day statWI 
1 2190 55.0 F 2 0 15/F/0 21:30 Fail 8 Dead 
2 2205 54.7 F 3 0 37/F/0 14:25 Funct 483 Alive 
3 2206 47.8 M 4 A 40fMJA 8 :30 Funct 493 Alive 
4 2228 65.3 F 4 A 47/F/A 27:11 Fail 3 Dead 
5 2254 58.6 M 4 0 25fMJO 15:39 Funct 457 Alive 
6 2260 33.6 M 4 0 51fMJO 15:55 Funct 452 Alive 
7 2281 59.9 F 4 A 61fMJA 11 :48 Funct 438 Alive 
8 2284 58.0 M 3 AB 34fMJAB 16:05 Funct 435 Alive 
9 2290 55.3 M 4 0 21fMJO 21:18 Fail 95 Alive 
10 2308 29.5 M 3 AB 54/F/AB 11 : 11 Fail 54 Dead 
11 2311 65.1 F 3 B 53/F/B 18:27 Fail 245 Dead 
12 2319 58.3 F 4 A 30/F/A 7:47 Fail 0 Alive 
13 2363 42.2 F 4 0 30/F/0 16:22 Funct 370 Alive 
14 2372 46.5 M 4 A 43/F/A 18:40 Fail 0 Dead 
15 2387 43.5 F 4 0 22!M10 19:01 Funct 353 Alive 
16 2394 83.7 F 4 0 18fMJO 7:30 Fail 14 Dead 
17 2427 47.9 F 4 0 18fMJO 18:36 Fail 17 Dead 
18 2440 53.5 F 3 AB 16/F/AB 12:33 Funct 305 Alive 
19 2460 50.9 M 4 A 47/F/A 18:42 Funct 295 Alive 
20 2461 63.0 M 4 0 54fM/0 16:51 Fail 19 Dead 
21 2472 51.1 M 4 A 10fMJA 14:01 Fail 126 Dead 
22 2491 53.6 F 4 0 IlfMJO 10:26 Funct 273 Alive 
23 2495 49.7 F 4 A 37/F/A 18:32 Funct 268 Alive 
24 2522 43.7 F 4 A 21fMJA 10:44 Funct 252 Alive 
25 2538 44.0 F 3 A 50fMJA 15 :21 Fail 10 Alive 
26 2592 37.6 M 4 0 22!M10 14 :33 Funct 203 Alive 
Fail = failed; Funct = functioning; NA = not available; CIT = cold ischemic time; UNOS = United Network of Organ 
OL T = orthotopic liver transplantation. 
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Sharing; 
crossmatch-positive cases and 188 to 515 days for the control 
patients. The clinical results have been reported in detail 
elsewhere (5) , as have the management policies (8). 
Daily intravenous doses of 0.1 mglkg of FK 506 and 20 mg 
methylprednisolone were begun during surgery. Starting daily 
oral doses were 0.30 mglkg FK 506 and 20 mg prednisone. The 
prednisone was tapered after 2 weeks if the postoperative 
course was uncomplicated. Cellular rejection episodes were 
treated by increasing the maintenance dose of FK 506, if this 
was possible without nephrotoxicity. If necessary, the FK 506 
adjustments were followed with a 1 gm bolus of intravenous 
methylprednisolone. Refractory rejection was treated with a 
5-day course of high-dose methylprednisolone, starting at 200 
mg with daily decrements of 40 mg. Nonresponsive patients 
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were given a 5-day course of 10 mg/day ofOKT-3, elevation of 
baseline steroids above 20 mg/day or both and the addition of 
azathioprine. 
Laboratory parameters followed daily for 30 days were 
platelet counts, normal greater than 150 x 1Q3/mm3; total 
bilirubin, normal less than 1.2 mg/dl; AST, normal less than 34 
lUlL; alkaline phosphatase, normal less than 100 lUlL; and 
-y-glutamyl transpeptidase (GGTP), normal less than 40 lUlL. 
Patients with graft failure or death during the first 30 days 
were excluded from only the analyses of liver function and 
platelet counts. The results of these analyses were expressed as 
median values (see Fig. 1). 
The survival rates of grafts and patients were calculated by 
the life table method of Kaplan-Meier. Differences in survival 
curves were measured with the generalized Wilcoxon test. 
Statistical comparisons were made by Student's t test and by 
X2 analysis. 
Routine and ImmunopatMrogical Studies. Liver allograft 
biopsy samples were obtained immediately before and 60 to 90 
min after complete revascularization. Biopsies were subse-
quently performed when clinically indicated by an elevation of 
liver function test results, by changes in the color or quantity 
of bile production, or by the clinical suspicion that a problem 
in the graft was responsible for an unsatisfactory recovery. 
Specimens generated in the 26 crossmatch-positive cases 
included 7 failed allografts and 110 needle biopsy samples. In 
the 52 crossmatch-negative cases, there were 3 failed allografts 
and 191 needle biopsy specimens. 
Histological sections were routinely cut at 4 !Lm and stained 
with hematoxylin and eosin. Selected sections were stained 
with trichrome and periodic acid-Schiff with diastase di-
gestion. All slides were reviewed independently by two of us 
(A. J. D. and K. N.). 
Portal tract inflammation, hepatocyte ballooning and sinu-
soidal neutrophilia were graded on a scale of 0 to 3. The 
composition of the infiltrate, when present, was labeled as 
polymorphonuclear, mononuclear, mixed, eosinophilic or 
other. Neutrophilic, mononuclear portal or central venulitis; 
neutrophilic, mononuclear or necrotizing arteritis; bile duct 
proliferation; platelet margination and thrombi; hepatocyte 
necrosis; and centrilobular congestion or hemorrhage were 
scored as present or absent. Equivocal findings were scored as 
negative. The distribution of necrosis was also noted. Any 
differences in the pathological assessment of the specimens 
were resolved by a joint review and consultation with other 
experienced pathologiBts. 
The pathological specimens were divided into five postop-
erative periods (days 0 to 10, 11 to 20, 21 to 30, 31 to 60 and 
61 to 120). All failed allograft tissue specimens were stained 
with a direct immunofluorescent (frozen tissue) method for the 
presence of IgG, IgM, 19A, Clq, C3, C4, ~-macroglobulinI 
transferrin and fibrinogen. Postreperfusion needle biopsy 
specimens from patients who lost their grafts because of 
suspected humoral rejection were stained for IgG, IgM, Clq 
and fibrinogen by use of an indirect immunoperoxidase 
technique on formalin-fixed, paraffin-embedded tissues. 
Hi.tometric Analysi. of Portal Arteries. Previous studies of 
animal kidney allografts (9-11) and of human livers (6) have 
suggested that arterial spasm is an important pathophysio-
logical mechanism of antibody-mediated graft damage. We 
reasoned that arteries in spasm should have an increased ratio 
of arterial wall thickness to vessel diameter. Therefore 
identical protocol sections (12) of all failed allograft specimens 
were blindly examined to assess the relationship between the 
wall thickness and the diameter of hepatic arteries. With a 
randomly selected area (200 mm2 ) of the identical hematoxylin 
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FIG. 1. Postoperative platelet counts (PLT) and liver function test 
values for total bilirubin (TB), AST, alkaline phosphatase (ALP) and 
-y-glutamyl transpeptidase (GGTP). n = 18 for each point in the 
crossmatch-positive group and n = 46 for the croBsmatch·negative 
patients. 
and eosin slides, the size of the only or the largest artery in the 
portal tract was determined by measuring the shortest 
diameter of the vessel to the outer extent of the media (outer 
diameter) and to the internal elastic lamina (internal diam-
eter). The thickness of the arterial wall was then calculated, 
and the results were expressed as a ratio. 
RESULTS 
Early Platelet Counts and Graft Function. Exclusive 
of the eight cases (31%) in which the grafts failed in 
fewer than 30 days, the peak AST levels immediately 
after transplantation in crossmatch-positive patients 
were actually lower than those in the control patients, of 
which six (17%) were excluded because of graft loss or 
patient death in fewer than 30 days (Fig. 1). This was 
partly a statistical artifact from the disproportionate 
culling of cases in the crossmatch-positive group. 
Median total bilirubin levels gradually declined in the 
crossmatch-negative patients throughout the 30 days, 
but two relative peaks were observed in the crossmatch-
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FIG. 2. Postreperlusion needle biopsy specimen from orthotopic liver transplantation no. 2284 demonstrating platelet margination along the 
central vein endothelium and in the lumen. This finding was most common in the crossmatch·positive patients immediately after reperfusion 
and was identical to that observed in sensitized rodents (Nakamura K, et ai, Manuscript submitted, 1992). <H & E; original magnification x 768.) 
positive patients between days 5 and 10 and again at day 
22 (Fig. 1). In the cases in which the grafts were retained 
for 30 days, the canalicular enzymes were similar in the 
two groups. kl with the AST, the results were skewed by 
the more frequent omission from the analysis of 30-day 
failures in the crossmatch-positive cohort. 
Peripheral platelet counts, which were similar in both 
groups before trnnspiantation, were depressed in the 
crossmatch-positive patients relative to those of the 
control patients during the entire first 30 days (Fig. 1). 
Thrombocytopenia in presensitized liver recipients has 
been reported previously (13). 
Incidence and Timing of Needk Biopsy Analysis. 
Exclusive of the intraoperative biopsies, which were 
uniformly distributed between the two groups, spec-
imens were obtained significantly more frequently from 
the crossmatch-positive patients on postoperative days 1 
to 10 (p < 0.01). Seventeen (77%) of these 26 patients 
provided 19 biopsy specimens during this interval vs. 19 
(42%) of the 52 control patients from whom 21 biopsy 
specimens were obtained. The same difference was seen 
between days 21 and 30, corresponding to the secondary 
peak of allograft dysfunction in the sensitized patients. 
In addition to the increased frequency, the average time 
of the first postoperative biopsy was earlier in the 
crossmatch-positive patients (mean 9 ± 8 days; median 
6 days) than in the control group (mean 14 ± 17 days; 
median 11 days; p < 0.05). 
Only 25 patients in the combined groups were not 
subjected to biopsy during the first 14 days. Eight of 
these patients had early graft failure. In the other 17, the 
postoperative course was uneventful. Among these 17 
patients with particularly benign courses, there were 
only two with a positive crossmatch. The first postop-
erative biopsies in these patients were on days 21 and 37. 
The other 15, who were crossmatch negative, had their 
first biopsy performed between days 15 and 30 (n = 11) 
or at day 120 (n = 4). 
Biopsy Findings and Pathologkal Diagnoses. In the 
intraoperative biopsy specimens obtained after reper-
fusion, statistically significant differences were noted in 
the patients sensitized for vascular platelet aggregation 
(Fig. 2; 33% vs. 5%; p < 0.05). Later, cholangiolar 
proliferation (Fig. 3) was seen more frequently in the 
sensitized patients in the third time period (80% vs. 14%; 
p < 0.05), and portal venulitis, including but not limited 
to neutrophils (Fig. 4), was seen more frequently in the 
first time period (50% vs. 23%; p < 0.05). Neutrophilic 
or necrotizing arteritis with or without fibrinoid degen-
eration was not observed in any specimen. 
By use of previously published histological criteria 
(14-16), a higher percentage of crossmatch-positive 
patients had at least one biopsy specimen that dem-
onstrated acute cellular rejection during the first 30 
days compared with control patients. This difference 
was statistically significant (p < 0.05) during only the 
first 10 days. In addition, the first biopsy-proved di-
agnosis of acute cellular rejection occurred on day 
9 ± 6 (median 6 days) in the crossmatch-positive pa-
tients compared with day 14 ± 6 in the control group 
(p < 0.05). 
A scatter plot of the cold ischemic time vs. the severity 
of preservation injury indicated that during the first and 
second periods (p < 0.05), the crossmatch-positive cases 
more often demonstrated a more severe form of preser-
vation injury as previously defined (12). This finding was 
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FIG. 3. Needle biopsy specimen of liver allograft from orthotopic liver transplantation no. 2309, 17 days after transplantation. This biopsy 
specimen was obtained 9 days after treatment of acute cellular rejection. Note the marked cholangiolar proliferation. Centrilobular hepatocyte 
swelling was also present. These two findings are often attributed to preservation or ischemic injury but were much more common in the 
crossmatch-positive patients despite similar preservation times. (H & E; original magnification x 192.) 
FIG. 4. Needle biopsy specimen of liver allograft from orthotopic liver transplantation no. 2284, 9 days after transplantation. Although portal 
localization of mononuclear cells has been emphasized as a component of cellular rejection, neutrophils, as a component of the population, were 
more common in the crossmatch-positive patients. (H & E; original magnification x 480.) 
true even though no difference was noted in the cold 
ischemic time for the two cohorts (Fig. 5). 
Clinicopathological Correlations. A statistically sig-
nificant difference was seen for both primary graft 
(p < 0.01) and patient (p > 0.05) survival (Fig. 6). At 
the time this article was written (August 1991),9 (35%) 
of the 26 crossmatch-positive patients and 7 (15%) of the 
52 control patients had died. 
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FIG. 5. Relationship between the cold ischemic time and the severity of preservation injury present in allograft biopsy specimens. 
100 
90 
80 
70 
iii 
> 
~ 60 
::J 
(/J 50 
it 40 
3Q 
20 
10 
0 
0 100 200 
Control 
Cronmatch Poaillve 
____ Pallent Survival 
----Graft Survival 
300 400 500 
Daya aft.r lranaplant.llon 
FIG. 6. Primary graft and patient survival curves for the crossmatch-positive patients vs. controls. 
The pathological findings in grafts retrieved at the 
time of retransplantation were analyzed separately from 
those obtained at autopsy. 
GraftB Retrieved at RetralUlplantation. In the 
crossmatch-negative group, 3 (6% of the original) grafts 
failed, leading to retransplantation within 180 days; the 
time of failure and retransplantation was 94 ± 87 days. 
By comparison 7 (27%) grafts in the crossmatch-positive 
group failed after a mean of 42 (± 51) days. 
The pathological findings in the failed allografts from 
both groups are summarized in Table 3. No correlation 
was detected between the underlying liver disease and 
graft failure. In the crossmatch-positive patients, all but 
two of the grafts showed portal inflammation with 
neutrophilia and cholangiolar proliferation. Focal large 
hilar bile duct, necrosis with biliary sludge (Fig. 7), or 
both and organized intrahepatic portal vein and arterial 
thrombi were also present in 5 of the 7 failed grafts from 
crossmatch-positive patients. 
In the grafts from these sensitized patients, the most 
conspicuous vascular findings were in the arteries 
and peribiliary vascular plexus. Arterial findings in-
cluded a thickened media with medial myocyte vacu-
olization and marked endothelial cell hypertrophy, at 
times with platelet margination coating the luminal 
surface (Fig. 8). Platelet margination was present in 
all but two of the grafts from sensitized patients but 
not in any of the controls. Occasionally, recanalized 
arterial thrombi also were seen but necrotizing or 
neutrophilic arteritis was not seen. Vascular channels 
in the peribiliary plexus were distended by macro-
phages, RBCs and fewer neutrophils. Nearby, large bile 
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FIG. 7. Section of hilum of failed liver allograft from orthotopic liver transplantation no. 2474. Note the bile duct necrosis with bile lea&age 
and intraluminal biliary sludge. An artery with the characteristic changes described above is present in the lower left comer. (H & E; ~al 
magnification x 77.) 
TABLE 3. Pathological findings in failed liver allograft obtained at the tilne of retrllDBplantatioD 
Graft 
Patient no. crr survival 
(OLT no.) Croaamatch (min) (days) Pathological fiDdiDp 
12 (2319) 
4 (2228) 
1 (2198) 
25 (2538) 
10 (2309) 
9 (2290) 
21 (2472) 
115 (2283) 
120 (2313) 
109 (2240) 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Positive 
Negative 
Negative 
Negative 
467 
1631 
1298 
921 
671 
1278 
841 
1843 
647 
698 
0 
3 
6 
10 
54 
95 
126 
2 
68 
111 
Widespread coagulative necrosis with intrahepatic venular thrombi 
Arterial thrombosis; imperfect arterial anastomosis 
Severe predominantly neutrophilic and lymphoblaBtic portal infiltrate with 
focal intrahepatic vaBcular thrombi and infarcts 
Hepatic artery thrombosis at anaBtomosis (technical); severe acute cellular 
rejection with prominent neutrophilia 
Focal bile duct necrosis with prominent neutrophilic portal inflammation 
and biliary sludge 
Focal intrahepatic large bile duct necrosis with biliary sludge; recent and 
remote intrahepatic thrombi in portal veins; superimposed cytomegalo-
virus infection (rare) 
Focal intrahepatic bile duct necrosis with organized intraarterial thrombi 
and small bile duct loss 
Portal vein thrombosis and focal hilar hepatic artery necrosis (technical) 
Acute cellular rejection with centrilobular necrosis and fibrosis 
Severe atherosclerosis of arterial graft with superimposed thrombosis 
CIT = cold ischemic time; OL T = orthotopic liver transplantation. 
duct walls were focally necrotic and contained biliary 
sludge. 
Gra{fs Retrieved at Autopay. Four patients un-
derwent postmortem examination; three were in the 
crossmatch-positive group (two after retransplanta-
tion) , and one was in the control group. The primary 
cause of death for each is listed in Table 4. No major 
differences in the causes of death were noted between 
the two groups. 
Arterial Wall Thickness. Arterial wall thickness and 
diameter ratios were measured in the grafts retrieved at 
retransplantation (Fig. 9). The ratios were significantly 
higher in the crossmatch-positive patients than in the 
control patients (p < 0.05). 
Immunofluorescence and fmmunope~ Find-
ings. Only one crossmatch-positive graft that failed on 
the same day of transplantation contained detectable, 
specific immune deposits (see Table 3). Relativeiy faint 
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FIG. 8. Section of failed liver allograft from orthotopic liver transplantation no. 2309, 54 days after transplantation. Note the marked medial 
thickening, luminal narrowing and medial myocyte vacuolization (indirect evidence of spasm). This finding was present in many, but not all, 
arteries in sections from the deep hilum of the liver. (H & E; original magnification x 480.) 
Patient no. 
(OLT no.) Cra8llmatch 
14 (2372) Positive 
16 (2394) Positive 
17 (2427) Positive 
20 (2461) Positive 
1 (2190) Positive 
4 (2220) Positive 
10 (2309) Positive 
21(2472) Positive 
11 (2311) Positive 
149 (2553) Negative 
126 (2384) Negative 
109 (2240) Negative 
127 (2381) Negative 
134 (2456) Negative 
144 (2500) Negative 
llO (2292) Negative 
OLT = orthotopic liver transplantation. 
aAutopsy not done. 
Patient 
survival 
(da)'ll) 
0 
14 
17 
19 
24 
56 
96 
141 
245 
8 
25 
171 
219 
222 
253 
307 
TABLE 4. Cause of death 
Graft in 
place at 
time oC death 
First 
First 
First 
First 
Second 
Second 
Second 
Second 
First 
First 
First 
Second 
First 
First 
First 
First 
Cause oC death 
Surgical complicationa 
Gastrointestinal bleed.inga 
Candida sepsis and cerebral bleed.inga 
Candida sepsis 
Pseudomonas sepsis and respiratory failurea 
Hepatorenal failure with posttransplantation lym. 
phoproliferative disorder 
Pseudomonas sepsis and kidney failurea 
Sepsis (Candida and Staphylococcus) 
Sepsis with mycotic aneurysma 
Patient never awoke from comaa 
Sepsis" 
Aspergillosis 
Pneumoniaa 
Recurrent hepatitis Ba 
Intracerebral hemorrhage and metastatic diseasea 
Cryptococcal meningitis" 
granular IgG, Clq and C3 deposits were present, pre-
dominantly in the sinusoids, with focal weak. deposits in 
hepatic arteries. Portal and central veins generally 
tested negative for these deposits. No significant 
immune deposits were present in any of the failed grafts 
in the other cross match-positive cases except for weak, 
questionable positivity on the basement membrane and 
on the epithelial cells of bile ducts. 
Biopsy specimens obtained in the early postoperative 
period (1 to 10 days) either tested negative or showed 
faint granular sinusoidal deposits similar to those 
described above. However, the immunoperoxidase tech-
nique used on the needle biopsy specimens may have 
been less sensitive than the direct immunofluorescence 
technique used on the failed allografts above. No 
immune deposits were detected in any of the 
• 
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crossmatch-negative grafts with direct immunofluores-
cence on frozen tissue. 
DISCUSSION 
In kidney allografts the adverse effect of preformed 
donor antibodies was first shown with the demon-
stration that ABO-mismatched kidneys often were 
rejected immediately by a process presumed to involve 
graft antibody RBC isoagglutinins (17). Lymphocyto-
toxic antibodies (18-21) and possibly reticuloendothelial-
specific (22) antibodies have also been shown to have 
similar effects. The target of destruction is the kidney 
microvasculature, which is ruined and plugged with 
thrombi so quickly that the descriptive term hyperacute 
rejection has been applied. Disparate xenografts are 
thought to be rejected by a similar mechanism, and the 
preformed antibodies, formed blood elements and 
clotting factors are sequestered in the transplant 
(23-25). 
Although the same rapid sequestration occurs in the 
transplanted liver in such experiments (23, 24), hyper-
acute rejection of liver allografts is difficult to produce 
experimentally (26,27) and rarely occurs clinically (1-5). 
Nevertheless, the adverse effect of preformed antibody 
states on the transplanted liver has been increasingly 
acknowledged, first with the recognition that the prog-
nosis after liver transplantation is degraded if ABO-
incompatible donors are used (2, 6, 28, 29) and then with 
isolated descriptions of primary liver graft nonfunction 
in patients with lymphocytotoxic antibodies (2, 30-32). 
Subsequently, an increased graft loss at a later time 
after surgery in cytotoxic crossmatch-positive cases was 
reported (4, 5). In addition, controlled experimental 
animal studies have shown that accelerated liver re-
jection can be reliably induced by prior recipient sensi-
tization (33, 34). Finally, Weber et al. (13) demonstrated 
a remarkable increase in the need for blood and blood 
product transfusions in patients with crossmatch-
positive liver donors. 
Despite this evidence, the role of lymphocytotoxic 
antibodies in the cause of humoral rejection after liver 
transplantation has been confused in the past by several 
factors. One factor has been the failure to differentiate 
between the lymphocytotoxic antibodies of the IgG class, 
which predispose to humoral rejection, and the IgM 
antibodies, which may not. The possibly irrelevant IgM 
antibodies can be eliminated as an artifact by treating 
the test sera with DTT (7,35), as was done in the present 
study. We have also recently shown the greater de-
structive potential of IgG alloantibodies in a small-
animal model of hepatic humoral rejection (Furuya 
et al., Unpublished observations, January 1992). 
Our study provides pathological confirmation that 
IgG lymphocytotoxic antibodies can adversely affect the 
human liver allograft, with an array of morphological 
consequences. Although cellular rejection is frequently 
superimposed, the histopathological pattern of injury on 
needle biopsy cannot be described as unique because 
many of the characteristic alterations are similar to 
those observed in sepsis and preservation injury (12). 
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FIG. 9. Ratio of arterial wall thickness to vessel diameter in failed 
grafts from crossmatch-positive patients vs. controls. 
The changes include the appearance of cholangioles with 
acute cholangiolitis, centrilobular hepatocyte swelling 
and hepatocanalicular cholestasis, often combined with 
cellular rejection. Additional findings described below 
are present in the hilum of failed allografts that were not 
accessible by biopsy evaluation. 
The pathophysiology of the observed cbanges could 
not be fully explained by use of the uncontrolled, 
clinically directed biopsy samplings. However, the acute 
injury appears to be related to mechanical occlusion of 
the microvasculature (36) and functional narrowing of . 
the arterial tree because of immunologically mediated 
vasoconstriction (6, 32), as has been reported in hyper-
acutely rejecting kidneys (9-11, 37). This injury can 
manifest as focal intrahepatic infarcts and large bile duct 
necrosis followed later by periductal fibrosis and stric-
turing. The appearance of cholangioles with acute 
cholangiolitis is considered by us to be a stereo typic 
regenerative response to injury, particularly when the 
periportal hepatocytes are involved. 
Nevertheless, the difficulty of studying pathophysi-
ology from noncontrolled clinical tissue samples re-
mains. We have therefore developed a clinically relevant 
small-animal model to address many of the issues raised 
by this study (Nakamura et al ., Unpublished observa-
tions, February 1992). 
The large liver mass and the presence of a second 
(portal) source of blood flow may partially explain its 
ability to withstand the initial insult of a positive 
crossmatch better than do the kidney and other organs 
that have an exclusively arterial supply and undergo 
infarction as an end result. However, it appears that the 
liver may behave as two organs. The first is the hepatic 
parenchyma with a sinusoidal vasculature, which may 
be more resistant because of its unique antigenic 
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composition, the presence of Kupffer cells and possibly 
the release of soluble mediators from Kupffer cells, 
which could influence the inflammatory response. 
The biliary tree, on the other hand, may behave more 
similarly to kidney and heart grafts because of its 
arterial only type circulation and the presence of a more 
conventional arteriolar and capillary network. A con-
tinued antibody-mediated insult to the arterial tree and 
peribiliary vascular plexus could account for the duc-
topenia without cholangiolar proliferation seen later in 
grafts that have survived despite a positive crossmatch 
(38, 39). 
In a previous publication (40), we outlined restrictive 
criteria for the histopathological diagnosis of hyperacute 
rejection. These criteria include rapid graft failure, 
consistent and predictable histopathological and immu-
nofluorescent changes, demonstrable presensitized state 
with lymphocytotoxic antibodies and elution of donor-
specific antibodies from the failed graft. It is clear that 
all of these conditions rarely can be documented, as was 
emphasized earlier (30), especially the demonstration of 
convincing immunofluorescence findings. The lack of 
significant deposits may be related to the less-sensitive 
immunoperoxidase technique used for postreperfusion 
biopsies. However, the failed allografts were examined 
by the more-sensitive direct immunofluorescent tech-
nique with frozen tissue and were also generally 
negative. 
Even with the treatment conditions used during this 
study, the majority of livers were able to pass through 
the perioperative period despite the handicap imposed 
by a positive cytotoxic crossmatch. In view of the associ-
ation of preformed antibodies with an enhanced immu-
nological injury, biopsy findings like those described 
above should elicit augmented immunosuppression be-
cause early and aggressive therapy can significantly alter 
the posttransplant course in crossmatch-positive pa-
tients. In addition, prophylactic treatment with prosta-
glandin to protect the microvasculature is under clinical 
trial, with encouraging preliminary results (41). Thus 
instead of avoiding transplantation in highly sensitized 
patients who may not be able to wait for a crossmatch-
negative donor, who is unlikely to be found, modification 
of the standard treatment protocol appears to be a sup-
portable option. 
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